Quantcast

Industry news that matters to you.  Learn more

The New York Genome Center And IBM Watson Group Announce Collaboration To Advance Genomic Medicine

The New York Genome Center (NYGC) and IBM (NYSE: IBM) recently announced an initiative to accelerate a new era of genomic medicine with the use of IBM’s Watson cognitive system. IBM and NYGC will test a unique Watson prototype designed specifically for genomic research as a tool to help oncologists deliver more personalized care to cancer patients.

$105 Million State-Initiated Collaboration Between the NY Genome Center and University at Buffalo Advances Medical Science in New York

The New York Genome Center (NYGC) announced that New York State Governor Andrew M. Cuomo proposed in his State of the State address last month a $105 million partnership between the NYGC and the University at Buffalo’s Center for Computational Research, enabling genetic discoveries that will potentially save lives by transforming how health care impacts patients. Governor Cuomo’s commitment to vastly enhancing the genomic medicine capabilities of New York State will have profoundly positive implications on health care effectiveness and efficiency for patients everywhere.

Utility Of Rubicon Genomics’ ThruPLEX-FD Kit Validated In Study Showing “Liquid Biopsy” Can Track Genomic Evolution Of Cancer In Response To Therapy

Rubicon Genomics, Inc., a leader in the development and commercialization of innovative sample-specific nucleic acid library preparation products used in research and clinical testing, recently reported that its ThruPLEXTM-FD Prep Kits contributed to the success of a breakthrough study recently published in Nature1 that showed that genomic data extracted from the plasma of cancer patients can be used to track drug resistance and potentially guide treatment.

Thomson Reuters Reveals New Strategies for Navigating Big Data in the Pharmaceutical Industry

The IP & Science business of Thomson Reuters, the world’s leading provider of intelligent information for businesses and professionals, recently released Big Data and the Needs of the Pharma Industry, a whitepaper offering new strategies for managing Big Data, most specifically by using an array of technologies to convert it into more meaningful, accessible Little Data. The paper highlights how the inherently data-driven pharmaceutical industry requires deep, broad information to feed drug R&D, but the way it processes Big Data is unique.

Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition

GenoSpace, PathGroup and the IP & Science business of Thomson Reuters recently announced an innovative initiative to develop and deliver a best-in-class personalized medicine service in oncology, the result of which will enable physicians to make more precise therapeutic recommendations for cancer patients.

This partnership combines resources, technology and expertise across the three organizations to integrate PathGroup’s SmartGenomics™ Next Generation DNA Sequencing and Cytogenomic Array with traditional pathology assays, providing a unique window into disease and patient treatment options through genetic profiling.

“Collaboration is essential to deliver more precise medical solutions in today’s Big Data environment,” said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences. “Our coalition with GenoSpace and PathGroup leverages each organization’s unique assets, making significant improvements in treatment options for cancer patients.”

PathGroup’s industry-leading anatomic, clinical and molecular pathology services are integrated with the unparalleled information on genes, variants and therapeutic implications from Thomson Reuters. These are then overlaid with GenoSpace’s advanced analytical and information integration capabilities to place this diverse data into context. Oncologists will soon start receiving individualized reports that provide targeted information to help identify the best possible therapy for their patients.

“We have entered a new age of personalized medicine,” said Ben Davis, MD, Chairman, president and CEO of PathGroup. “It is one in which the unique genetic profile of each patient’s tumor, placed in the context of their disease, can help physicians select treatment options and improve outcomes. The GenoSpace and Thomson Reuters contributions to our SmartGenomics analyses add a highly sophisticated tool to our pathologist’s armamentarium in developing a patient genomic dossier.”

“One challenge in personalized medicine is assuring that what the physicians see is the most accurate and up-to-date information,” added Joseph Donahue, senior vice president of Thomson Reuters Life Sciences. “Thomson Reuters has always been focused on providing the most comprehensive information on genes and their functions, and we are delighted to be able to partner with PathGroup and GenoSpace to demonstrate how that information can be used to improve health care delivery.”

John Quackenbush, Ph.D., CEO of GenoSpace, said, “The GenoSpace FullView™ and GenoSpace for Clinical™ platforms integrate the vast pathology resources available at PathGroup with sequence and array data and information, tying in the extensive knowledgebase available through Thomson Reuters, to deliver concise, relevant and actionable reports to oncologists in a format that they find useful in making treatment decisions. By bringing together the complementary strengths of each company, we will be able to deliver a market-leading solution in personalized genomic medicine.”

Source: Thomson Reuters